This week marks the exciting launch of the PIPELINE project, a groundbreaking initiative dedicated to improving the health of pregnant people and infants across Europe. Recognising the critical need to include these populations in clinical research, PIPELINE aims to establish a robust platform for adaptive clinical studies.
Recent pandemics have starkly highlighted the significant gaps in research involving pregnant people and infants. These gaps often result in delays in developing effective and safe treatments for these populations. PIPELINE aims to address this by creating a network of clinical trial sites specifically trained to conduct research in this area.
A key component of PIPELINE is a proof-of-concept trial focusing on respiratory syncytial virus (RSV) immunisation in pregnant people and infants. This trial will serve as a model for future research, demonstrating the value of adaptive trial designs in this context.
“PIPELINE represents a significant step forward in advancing our understanding of how to protect and treat pregnant people and infants during health crises,” said Prof. Carlo Giaquinto, PIPELINE Coordinator.
By fostering collaboration across Europe and utilising cutting-edge methodologies, PIPELINE aims to not only improve the health of pregnant people and infants but also to strengthen the capacity for future research in this critical area.
Read the full press release here. The Italian version is available here